Yorhe(SZ:002795) Xin Jing Bao·2025-11-27 08:57Core Viewpoint - Yonghe Intelligent Control Co., Ltd. is divesting all its investments in private oncology hospitals, marking a complete exit from the healthcare sector due to ongoing financial struggles and poor performance of its medical assets [2][3][5]. Group 1: Divestment Details - Yonghe Intelligent Control has initiated the public transfer of 100% equity in its wholly-owned subsidiary, Kunming Medical Oncology Hospital, with a starting price of no less than 35.93 million yuan [3][4]. - This divestment is part of a broader strategy, as Yonghe has already attempted to sell its stakes in three other oncology hospitals since 2020, including Dazhou Medical Oncology Hospital, Liangshan High-tech Oncology Hospital, and Xi'an Medical Oncology Hospital [3][4]. - The financial performance of Kunming Medical has been poor, with revenues of 11.58 million yuan and a net loss of 6.59 million yuan for the first seven months of 2025, contributing to Yonghe's decision to sell [3][6]. Group 2: Financial Performance - Yonghe Intelligent Control's main business includes fluid control products, oncology precision radiation treatment, and photovoltaic battery production. The company reported a revenue of 1.01 billion yuan in 2021, marking a 55.71% increase [5]. - However, the company's financial situation deteriorated significantly from 2022 to 2024, with revenues declining from 990 million yuan in 2022 to 823 million yuan in 2024, and net losses increasing from 26.19 million yuan to 297 million yuan during the same period [6]. - The decline in performance is attributed to reduced income from the valve and fitting business, lower product gross margins, and high depreciation and labor costs [6][7]. Group 3: Strategic Shift - Following the divestment of its medical assets, Yonghe Intelligent Control is expected to refocus on its core business operations. The company has not yet communicated its future strategic direction or potential new growth areas [7].